VERVE THERAPEUTICS INC. - COMMON STOCK

Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 05:30:11 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

01 Dec 2023 15:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

28 Nov 2023 21:37:08 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

28 Nov 2023 15:01:51 By Nasdaq GlobeNewswire

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

07 Nov 2023 05:30:00 By Nasdaq GlobeNewswire

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

31 Oct 2023 05:01:28 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

23 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

26 Sep 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

21 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

18 Sep 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

10 Aug 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference

03 Aug 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

15 Jun 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

01 Jun 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day

23 May 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

15 May 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

09 May 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

03 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

02 Mar 2023 05:30:00 By Nasdaq GlobeNewswire